Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) (DeLOS II)

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
ClinAssess, University of Leipzig Identifier:
First received: July 27, 2007
Last updated: June 1, 2015
Last verified: June 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2015
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)